Bone Biologics Income Statement (2016-2017) | BBLG

Income Statement Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017
Revenue & cost
Revenue -0.31M-0.36M-0.36M-0.76M-0.96M-1.24M-1.46M
Operating items
Research & Development 4.68M2.32M2.47M0.70M1.19M0.42M0.23M0.35M
Selling, General & Administrative 4.43M2.02M1.38M-2.17M0.97M1.13M0.90M0.97M
Other Operating Expenses -0.00M-3.53M
Operating Expenses 9.10M4.34M3.86M3.11M2.16M-1.97M1.13M1.31M
Operating Income -9.10M-4.34M-3.86M-3.11M-2.16M1.97M-1.13M-1.31M
EBIT -9.10M-4.34M-3.86M-3.11M-2.16M1.97M-1.13M-1.31M
Non-operating items
Other Non Operating Income -2.84M-2.84M-2.84M-2.84M
Non Operating Income -3.16M-0.36M-0.36M-1.58M-0.76M-0.96M-1.24M-1.46M
Net income details
EBT -12.26M-4.70M-4.22M-4.70M-2.92M1.02M-2.38M-2.77M
Tax Provisions 0.00M0.00M-502.000.00M
Profit After Tax -12.26M-4.70M-4.22M-4.70M-2.92M1.02M-2.38M-2.77M
Income from Continuing Operations -12.26M-4.70M-4.22M-4.70M-2.92M1.02M-2.38M-2.77M
Consolidated Net Income -12.26M-4.70M-4.22M-4.70M-2.92M1.02M-2.38M-2.77M
Income towards Parent Company -12.26M-4.70M-4.22M-4.70M-2.92M1.02M-2.38M-2.77M
Net Income towards Common Stockholders -12.26M-4.70M-4.22M-4.70M-2.92M1.02M-2.38M-2.77M
Additional items
EPS (Basic) -0.35-0.12-0.11-0.12-0.080.26-0.61-0.71
EPS (Weighted Average and Diluted) -0.120.25
Shares Outstanding (Weighted Average) 34.69M38.15M38.83M37.63M38.83M3.88M3.89M
Shares Outstanding (Diluted Average) 38.15M4.07M
EBITDA -9.10M-4.34M-3.86M-3.11M-2.16M1.97M-1.13M-1.31M
Interest Expenses 0.31M0.36M0.36M0.76M0.96M1.24M1.46M
Tax Rate -0.01%-0.02%0.01%0.16%